AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28114604
Drug: Imiquimod cream,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod cream, 5% applied topically once per day for 4 consecutive days on specified cycles for 12 weeks, combined with albumin bound paclitaxel, 100 mg/m2 intravenously on days 1, 8, and 15, repeated every 28 days for 12 weeks
Trial: 28114884
Drug: Maternal vascular
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal vascular endothelial growth factor (VEGF) gene therapy
Trial: 28114898
Drug: Initial empirical
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial empirical antifungal therapy
Trial: 28114898
Drug: Initial pre-emptive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial pre-emptive antifungal therapy
Trial: 28114898
Drug: Initial targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial targeted antifungal therapy
Trial: 28114962
Drug: COPE intervention
RxNorm normalized name: Copernicia prunifera whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COPE intervention (Caregivers of cancer Outpatients' Psycho-Education support group therapy), comprising four weekly sessions targeting psychoeducation, skills training, and supportive therapy.
Trial: 28116595
Drug: Early fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early fluid administration (total fluid infused in the first 6 hours)
Trial: 28117498
Drug: Insomnia (measured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insomnia (measured using The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 version)
Trial: 28117498
Drug: Anxiety, type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anxiety, type of treatment, back muscle strength, pain severity, and stage of treatment
Trial: 28117906
Drug: Integrative Cognitive-Affective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative Cognitive-Affective Therapy (ICAT-BN)
Trial: 28117906
Drug: Cognitive-Behavioral Therapy-Enhanced
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy-Enhanced (CBT-E)
Trial: 28119295
Drug: Margetuximab (0.1-6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Margetuximab (0.1-6.0 mg/kg for Regimen A, 10-18 mg/kg for Regimen B) administered by intravenous infusion, 3 of every 4 weeks for Regimen A or once every 3 weeks for Regimen B.
Trial: 28119763
Drug: Vonoprazan (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonoprazan (10 mg and 20 mg combined)
Trial: 28119821
Drug: Laronidase treatment
RxNorm normalized name: Laronidase
DrugBank: Laronidase (DB00090)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Laronidase treatment after immunosuppression regimen with cyclosporine and azathioprine
Trial: 28119821
Drug: Laronidase treatment
RxNorm normalized name: Laronidase
DrugBank: Laronidase (DB00090)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Laronidase treatment
Trial: 28119821
Drug: Cyclosporine (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (initial dose: 15 or 20 mg/kg/day) and azathioprine (initial dose: 2.5 or 5 mg/kg/day)
Trial: 28120036
Drug: Codrituzumab 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codrituzumab 2.5 mg/kg qw + Sorafenib 400 mg bid
Trial: 28120036
Drug: Codrituzumab 5
RxNorm normalized name: Codrituzumab
DrugBank: Codrituzumab (DB14843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codrituzumab 5 mg/kg qw + Sorafenib 400 mg bid
Trial: 28120036
Drug: Codrituzumab 10
RxNorm normalized name: Codrituzumab
DrugBank: Codrituzumab (DB14843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codrituzumab 10 mg/kg qw + Sorafenib 400 mg bid
Trial: 28120036
Drug: Codrituzumab 1600
RxNorm normalized name: Codrituzumab
DrugBank: Codrituzumab (DB14843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codrituzumab 1600 mg q2w + Sorafenib 400 mg bid
Trial: 28120036
Drug: Codrituzumab 1600
RxNorm normalized name: Codrituzumab
DrugBank: Codrituzumab (DB14843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codrituzumab 1600 mg qw + Sorafenib 400 mg bid
Trial: 28120158
Drug: Liposomal bupivacaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine, single 266 mg dose (cohort 1)
Trial: 28120158
Drug: Liposomal bupivacaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine, two 266 mg doses (cohorts 2-5)
Trial: 28120158
Drug: Liposomal bupivacaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine, repeated doses at 24, 48, or 72 hours after first dose
Trial: 28122201
Drug: PF-02545920, single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-02545920, single oral dose administration, dosage not specified
Trial: 28122648
Drug: Microbiota Transfer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microbiota Transfer Therapy (MTT) involving a 2-week antibiotic treatment, bowel cleanse, and extended fecal microbiota transplant (FMT) with a high initial dose followed by daily lower maintenance doses for 7-8 weeks.
Trial: 28122648
Drug: Microbiota Transfer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microbiota Transfer Therapy (MTT)
Trial: 28123778
Drug: Tocilizumab combination
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab combination therapy
Trial: 28123890
Drug: Activated and
RxNorm normalized name: hepatitis A inactivated and hepatitis B (recombinant) vaccine per 1 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated and expanded natural killer (NKAE) cells plus anti-myeloma drugs
Trial: 28125608
Drug: Salvia Miltiorrhiza
RxNorm normalized name: SALVIA MILTIORRHIZA ROOT
DrugBank: Salvia miltiorrhiza root (DB14337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvia Miltiorrhiza Depside Salt for Infusion (SMDS)
Trial: 28126019
Drug: Tele-EMS physician
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tele-EMS physician treatment (intervention group)
Trial: 28126019
Drug: Conventional EMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional EMS physician treatment (control group)
Trial: 28128878
Drug: Cooling treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooling treatments
Trial: 28129526
Drug: Androgens added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgens added to maintenance therapy
Trial: 28129526
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy without androgens
Trial: 28129783
Drug: 6-week Internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-week Internet-based self-help therapy intervention
Trial: 28130212
Drug: Pomalidomide 4
RxNorm normalized name: pomalidomide 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide 4 mg/d and dexamethasone 20 or 40 mg once per week
Trial: 28130212
Drug: Pomalidomide 2
RxNorm normalized name: pomalidomide 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide 2 mg/d and dexamethasone 20 or 40 mg once per week
Trial: 28131167
Drug: IPX066 (carbidopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPX066 (carbidopa and levodopa extended-release capsules)
Trial: 28131394
Drug: Soluble VAR2CSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble VAR2CSA protein vaccine
Trial: 28131785
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg intravenously every 2 weeks until disease progression or unacceptable toxicity.
Trial: 28131785
Drug: Nivolumab treatment-related
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab treatment-related adverse events.
Trial: 28131785
Drug: Nivolumab treatment-related
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab treatment-related deaths.
Trial: 28132845
Drug: ivacaftor treatment
RxNorm normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ivacaftor treatment (4 weeks)
Trial: 28132845
Drug: ivacaftor treatment
RxNorm normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ivacaftor treatment (48 weeks)
Trial: 28134742
Drug: HBV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV vaccine challenge after initial anti-HBs testing
Trial: 28135273
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated JE vaccine SA14-14-2
Trial: 28135777
Drug: Simeprevir (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simeprevir (150 mg) + Daclatasvir (60 mg) once daily for 12 weeks
Trial: 28135777
Drug: Simeprevir (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simeprevir (150 mg) + Daclatasvir (60 mg) once daily for 24 weeks
Trial: 28135777
Drug: Simeprevir (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simeprevir (150 mg) + Daclatasvir (60 mg)
Trial: 28137593
Drug: Ledipasvir-sofosbuvir for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir-sofosbuvir for 12 weeks (90/400 mg once daily)
Trial: 28137593
Drug: Ledipasvir-sofosbuvir for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir-sofosbuvir for 8 weeks (90/400 mg once daily)
Trial: 28138028
Drug: Chk1/2 inhibition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chk1/2 inhibition with prexasertib combined with EGFR inhibitor cetuximab and radiotherapy
Trial: 28138560
Drug: BTK inhibitor
RxNorm normalized name: BTK inhibitor CC-292
DrugBank: Spebrutinib (DB11764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTK inhibitor ibrutinib
Trial: 28139016
Drug: Intra-articular (IA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular (IA) Autologous Protein Solution (APS) 50 μl from a human donor
Trial: 28139235
Drug: Probability of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probability of pregnancy at 1 year after arrest of medical treatment
Trial: 28140719
Drug: Delanzomib (CEP-18770)
RxNorm normalized name: Delanzomib
DrugBank: Delanzomib (DB11956)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delanzomib (CEP-18770) at maximum tolerated dose (MTD) of 2.1 mg/m², administered on days 1, 8, and 15 in 28-day cycles.
Trial: 28143447
Drug: Indacaterol 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol 150 μg once-daily for 5 months
Trial: 28144789
Drug: AZD5363 combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5363 combined with docetaxel and prednisolone chemotherapy (DP)
Trial: 28144789
Drug: Docetaxel and
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel and prednisolone chemotherapy (DP)
Trial: 28146642
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (placebo or standard treatment)
Trial: 28148221
Drug: Seasonal adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seasonal adjuvanted influenza vaccine (Fluad™, Novartis) with five follow-up visits (day 0, 1/3, 7, 21, 70)
Trial: 28148281
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drugs (NSAIDs) usage
Trial: 28148281
Drug: Tumor necrosis
RxNorm normalized name: Tumor necrosis factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor necrosis factor (TNF) blockers usage
Trial: 28148635
Drug: High-dose immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation (HDIT/HCT)
Trial: 28150872
Drug: High-dose melphalan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose melphalan followed by HSCT
Trial: 28151941
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment group (training and support in intensive multifactorial treatment)
Trial: 28151941
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (intensive treatment and routine care)
Trial: 28152086
Drug: NKTT120 (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKTT120 (0.1 mg/kg, 0.3 mg/kg, 1 mg/kg)
Trial: 28152086
Drug: NKTT120 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKTT120 (0.3 mg/kg, 1 mg/kg)
Trial: 28152975
Drug: Cuff inflation
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cuff inflation to recommended volume (#3: 60 ml, #4: 80 ml, #5: 90 ml)
Trial: 28155045
Drug: Alisertib (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib (selective aurora kinase A inhibitor)
Trial: 28155203
Drug: Culturally adapted
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally adapted psychoeducation (CaPE) plus Treatment As Usual (TAU)
Trial: 28157063
Drug: Cumulative amounts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative amounts of harmful excipients (ethanol, propylene glycol, benzyl alcohol, parabens, acesulfame p, aspartame, glycerol, sorbitol, polysorbate-80) administered during hospitalization.
Trial: 28157173
Drug: Nickel patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nickel patch test in NCWS patients
Trial: 28158311
Drug: BI-505, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, administered as 5 doses totaling 43 mg/kg BW over a 7-week period.
Trial: 28158395
Drug: Oral challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral challenge with S. Paratyphi A at a dose of 1-5 × 10^3 CFU
Trial: 28158395
Drug: Oral challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral challenge with S. Paratyphi A at a dose of 0.5-1 × 10^3 CFU
Trial: 28158395
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment started when prespecified diagnostic criteria were met or at day 14 postchallenge
Trial: 28158463
Drug: Ramucirumab 6
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ramucirumab 6 mg/kg Q2W (N = 3)
Trial: 28158463
Drug: Ramucirumab 8
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ramucirumab 8 mg/kg Q2W (N = 6)
Trial: 28158463
Drug: Ramucirumab 10
RxNorm normalized name: ramucirumab 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramucirumab 10 mg/kg Q3W (N = 6)
Trial: 28158504
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) including tenofovir disoproxil fumarate
Trial: 28158551
Drug: Concurrent reactivations
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent reactivations of herpesviruses (CMV, EBV, HHV-6, HSV-1, HSV-2, VZV)
Trial: 28158551
Drug: Concurrent CMV
RxNorm normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent CMV and EBV reactivations
Trial: 28159192
Drug: rFIXFc prophylaxis
RxNorm normalized name: rFIXFc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rFIXFc prophylaxis (50-60 IU/kg) once per week, adjusted to ≤100 IU/kg per infusion or up to two times per week as needed
Trial: 28159512
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blockers (CCB) therapy
Trial: 28159590
Drug: Polygenic risk
RxNorm normalized name: polygalic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polygenic risk scores (PRS) for antidepressant efficacy
Trial: 28159590
Drug: Stratified by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stratified by antidepressant (escitalopram or citalopram)
Trial: 28159728
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of flaxseed lignan (secoisolariciresinol diglucoside; SDG) daily
Trial: 28159938
Drug: Sulfatinib formulation
RxNorm normalized name: SULFATINIB
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfatinib formulation 2 (50 and 200 mg capsules)
Trial: 28159938
Drug: Sulfatinib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfatinib (300 mg recommended phase II dose)
Trial: 28161120
Drug: Venetoclax (ramp-up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax (ramp-up treatment 20-200 mg) with posaconazole (20 mg)
Trial: 28161120
Drug: Venetoclax (reduced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax (reduced dose)
Trial: 28161570
Drug: Oral cholera
RxNorm normalized name: VIBRIO CHOLERAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cholera vaccine (Shanchol)
Trial: 28161570
Drug: No exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No exposure to oral cholera vaccine
Trial: 28162825
Drug: Quadrivalent live
RxNorm normalized name: influenza vaccine quadrivalent live 2015-2016 (2 yrs-49 yrs) 10exp6.5-7.5 FF unit/0.2 mL NASAL NASAL SPRAY SYRINGE (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent live attenuated influenza vaccine (Q/LAIV)
Trial: 28162825
Drug: Inactivated influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated influenza vaccine (IIV) recipients
Trial: 28163748
Drug: Conventional drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drug treatment with weight loss
Trial: 28164014
Drug: Percutaneous coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary interventions (PCI) performed in 175 Russian PCI centers; 531 PCI per 1,000,000 population; 101,451 stents placed (1.37 stents per PCI; 48,057 drug-eluting stents).
Trial: 28164367
Drug: Severe hyperglycaemia
RxNorm normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe hyperglycaemia (> 11.1 mmol/l) in people without diabetes
Trial: 28166794
Drug: Malaria treatment
RxNorm normalized name: Plasmodium malariae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Malaria treatment or any other medication within 14 days
Trial: 28166794
Drug: Insecticide spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insecticide spray within 7 days
Trial: 28168735
Drug: Imiquimod (IMQ)
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imiquimod (IMQ) pretreatment with NB-UVB therapy
Trial: 28168735
Drug: NB-UVB therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NB-UVB therapy alone
Trial: 28169974
Drug: Biological parenteral
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological parenteral treatment
Trial: 28169974
Drug: Nonbiological oral
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonbiological oral treatment
Trial: 28173784
Drug: Comprehensive approach
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive approach integrating clinical and functional status-based pathology and adapted rehabilitation prescription
Trial: 28174148
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam for conscious sedation
Trial: 28174191
Drug: Therapeutic ultrasound
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic ultrasound (1.3 MHz, mechanical index 1.3) for 10 minutes after intravenous injection of microbubble contrast agents (2×10)
Trial: 28174292
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal insulin spray
Trial: 28174487
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NAC) using oxaliplatin plus capecitabine (CapOX)
Trial: 28177438
Drug: TG4023 (MVA-FCU1)
RxNorm normalized name: MVA
DrugBank: TG4023 (DB06108)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG4023 (MVA-FCU1) at doses of 107, 108, or 4 × 108 p.f.u. via intratumoral injection
Trial: 28177438
Drug: 5-FC (flucytosine)
DrugBank: Flucytosine (DB01099)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-FC (flucytosine) at a dose of 200 mg/kg/day for 14 days
Trial: 28177438
Drug: TG4023/5-FC combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG4023/5-FC combination
Trial: 28177438
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment with TG4023 and 5-FC
Trial: 28178640
Drug: Alisertib (30,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib (30, 40, and 50 mg orally b.i.d., days 1-7 every 21 days) in combination with abiraterone and prednisone (AP)
Trial: 28179030
Drug: Sebelipase alfa
RxNorm normalized name: Sebelipase alfa
DrugBank: Sebelipase alfa (DB11563)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sebelipase alfa (0.35 mg/kg with intrapatient dose escalation up to 5 mg/kg, once weekly)
Trial: 28179439
Drug: Inhaled ATP
RxNorm normalized name: ATP
DrugBank: ATP (DB00171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled ATP
Trial: 28179439
Drug: Inhaled AMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled AMP